Novavax, Inc. (NVAX) reported a fourth-quarter 2023 loss of $1.44 cents per share, much wider than the Zacks Consensus Estimate of a loss of 49 cents. In the year-ago quarter, the company reported a loss of $2.28 per share.Revenues in the quarter amounted to $291.3 million, also missing the Zacks Consensus Estimate of $334.0 million. The top line declined 18.5% on a year-over-year basis.Quarter in DetailIn the reported quarter, the company recorded $251.4 million in product sales, reflecting a decrease of 1 ...

© 2024 NOVAVAX. All rights reserved. 1 | --- | --- | --- | --- | |--------------------------------------------|-------|-------|-------| | | | | | | | | | | | Fourth quarter & full | | | | | | | | | | | | | | | year 2023 financial results & operational | | | | | highlights | | | | | Nasdaq: NVAX \| February 28th, 2024 | | | | © 2024 NOVAVAX. All rights reserved. Q4 and FY 2023 Earnings call Erika Schultz Senior Director, Investor Relations John C. Jacobs President and Chief Executive Officer NovavaxTM (and a ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

For the quarter ended December 2023, Novavax (NVAX) reported revenue of $291.34 million, down 18.5% over the same period last year. EPS came in at -$1.44, compared to -$2.28 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $334.46 million, representing a surprise of -12.89%. The company delivered an EPS surprise of -193.88%, with the consensus EPS estimate being -$0.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Novavax Inc (NASDAQ:NVAX) missed top- and bottom-line estimates for the fourth quarter. The company noted its plans to cut costs, and still narrowed losses from the fourth quarter despite slowing Covid-19 vaccine demand. NVAX is down 26.3% to trade at $4.43 at last check.The shares have struggled to stay above penny stock territory, while their 200-day moving average has acted as long-term pressure. If these losses hold, NVAX could mark its worst daily percentage loss since December 2022. In the past 12 mon ...

Novavax (NASDAQ:NVAX) stock is falling hard on Wednesday as investors react to the vaccine company’s earnings report for the fourth quarter of 2024.Let’s dig into everything that has investors in NVAX stock disappointed today below!NVAX Earnings Hit StockNovavax reported earnings per share of -$1.44 during the quarter.That’s worse than the -35 cents per share that Wall Street was expecting.However, it is better than the -$2.28 from the same time last year.Revenue of $291.34 million also failed to meet the a ...

Novavax (NVAX) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $2.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -193.88%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.82 per share when it actually produced a loss of $1.26, delivering a surprise of 30.77%.Over the last four quarters, the company has surpasse ...

Vaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street's estimates and reiterated plans to cut costs as it fights to stay afloat. Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech company's Covid vaccine – its only marketable product – and other products that combat the virus continue to plummet worldwide. Here's what Novavax reported for the fourth quarter compared with what Wall Street was expe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of Registrant as specified in its charter) Delaware 22-2816046 (State of incorporation) (I.R.S. ...

Many investors have seen Novavax (NVAX 3.97%) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of the biggest coronavirus vaccine hopefuls, Novavax's shares soared by more than 2,700% in 2020 -- then plummeted as the development and commercialization of the company's COVID vaccine candidate lagged behind its rivals.The late arrival of Novavax's vaccine on the market meant the company missed out on the early mult ...